1. Melmed S. Pituitary-Tumor Endocrinopathies. N Engl J Med.
2020;382(10):937-950.
2. Nieman LK, Biller BM, Findling JW, et al. The diagnosis of
Cushing’s syndrome: an Endocrine Society Clinical Practice
Guideline. J Clin Endocrinol Metab. 2008;93(5):1526-1540.
3. Gjerstad JK, Lightman SL, Spiga F. Role of glucocorticoid negative feedback in the regulation of HPA axis pulsatility. Stress.
2018;21(5):403-416.
4. Forman BH, Marban E, Kayne RD, et al. Ectopic ACTH syndrome due to pheochromocytoma: case report and review of the
literature. Yale J Biol Med. 1979;52(2):181-189.
5. Terzolo M, Alì A, Pia A, et al. Cyclic Cushing’s syndrome due
to ectopic ACTH secretion by an adrenal pheochromocytoma. J
Endocrinol Invest. 1994;17(11):869-874.
6. Oh HC, Koh JM, Kim MS, et al. A case of ACTH-producing
pheochromocytoma associated with pregnancy. Endocr J.
2003;50(6):739-744.
7. Danilovic DL, Brandão Neto RA, D’Abronzo H, Menezes MR,
Lucon AM, Mendonca BB. Ectopic ACTH syndrome caused by
pheochromocytoma: computed tomography-guided percutaneous ethanol injection as an alternative treatment. J Endocrinol
Invest. 2007;30(9):780-786.
8. Brenner N, Kopetschke R, Ventz M, Strasburger CJ, Quinkler M,
Gerl H. Cushing’s syndrome due to ACTH-secreting
pheochromocytoma. Can J Urol. 2008;15(1):3924-3927.
9. Cassarino MF, Ambrogio AG, Pagliardini L, et al. ACTH secreting pheochromocytoma with false-negative ACTH
immunohistochemistry. Endocr Pathol. 2012;23(3):191-195.
10. Sakuma I, Higuchi S, Fujimoto M, et al. Cushing syndrome
due to ACTH-secreting pheochromocytoma, aggravated by
glucocorticoid-driven positive-feedback loop. J Clin Endocrinol
Metab. 2016;101(3):841-846.
11. Falhammar H, Calissendorff J, Höybye C. Frequency of
Cushing’s syndrome due to ACTH-secreting adrenal medullary
lesions: a retrospective study over 10 years from a single center.
Endocrine. 2017;55(1):296-302.
12. Inoue M, Okamura K, Kitaoka C, et al. Metyrapone-responsive
ectopic ACTH-secreting pheochromocytoma with a vicious
Downloaded from https://academic.oup.com/jes/article/5/6/bvab055/6205391 by Kobe Universtiy Library user on 16 September 2022
USP48, and BRAF variants in our study. Further investigation is needed to elucidate the underlying mechanism
of GC-mediated positive feedback, including the methylation status of the POMC promoter region in these
ACTHomas.
In this study, we performed a retrospective multicenter
analysis, showing that the prevalence of paradoxical rise
both after LDDST and HDDST was 8.7%, which is more
than expected. In these paradoxical rise subjects, tumor
diameter was larger and MRI findings exhibited a more invasive than decreased group. These data support the previous reports that showing the recurrent rates is higher in
cyclic Cushing disease [43].
In conclusion, we presented a case of CD that clearly
showed GC-driven positive feedback, both clinically
and experimentally. Intriguingly, tumor shrinkage in this
case was seen during metyrapone treatment, suggesting
GC positive feedback response not only to ACTH secretion but also to tumor proliferation. Further studies are
needed to explore the detailed molecular mechanisms by
which these tumors have GC-dependent tumor progression and ACTH production. Regarding the prevalence of
ACTHoma with a GC positive feedback loop, our CD cohort study discovered it in 8.7% of the 92 patients with
CD, which is not infrequent, thereby suggesting the presence of a new subtype of CD different from the majority
of CD cases.
Journal of the Endocrine Society, 2021, Vol. 5, No. 6
Journal of the Endocrine Society, 2021, Vol. 5, No. 6
28. Fukasawa M, Sawada N, Miyamoto T, et al. Laparoscopic unilateral total and contralateral subtotal adrenalectomy for bilateral
adrenocorticotropic hormone-secreting pheochromocytoma:
report of a rare case. J Endourol Case Rep. 2016;2(1):232-234.
29. Loh KC, Gupta R, Shlossberg AH. Spontaneous remission of
ectopic Cushing’s syndrome due to pheochromocytoma: a case
report. Eur J Endocrinol. 1996;135(4):440-443.
30. Iwayama H, Hirase S, Nomura Y, et al. Spontaneous adrenocorticotropic hormone (ACTH) normalisation due to tumour
regression induced by metyrapone in a patient with ectopic
ACTH syndrome: case report and literature review. BMC
Endocr Disord. 2018;18(1):19.
31. Ayroldi E, Cannarile L, Delfino DV, Riccardi C. A dual role for
glucocorticoid-induced leucine zipper in glucocorticoid function: tumor growth promotion or suppression? Cell Death Dis.
2018;9(5):463.
32. Yano A, Fujii Y, Iwai A, Kageyama Y, Kihara K. Glucocorticoids
suppress tumor angiogenesis and in vivo growth of prostate
cancer cells. Clin Cancer Res. 2006;12(10):3003-3009.
33. Lin KT, Sun SP, Wu JI, Wang LH. Low-dose glucocortic oids suppresses ovarian tumor growth and metastasis in
an immunocompetent syngeneic mouse model. PLoS One.
2017;12(6):e0178937.
34. Shinozawa T, Yoshikawa HY, Takebe T. Reverse engineering
liver buds through self-driven condensation and organization
towards medical application. Dev Biol. 2016;420(2):221-229.
35. Takebe T, Zhang B, Radisic M. Synergistic engineering: organoids
meet organs-on-a-chip. Cell Stem Cell. 2017;21(3):297-300.
36. Tuveson D, Clevers H. Cancer modeling meets human organoid
technology. Science. 2019;364(6444):952-955.
37. Korbonits M, Bujalska I, Shimojo M, et al. Expression of 11
beta-hydroxysteroid dehydrogenase isoenzymes in the human
pituitary: induction of the type 2 enzyme in corticotropinomas
and other pituitary tumors. J Clin Endocrinol Metab.
2001;86(6):2728-2733.
38. Riebold M, Kozany C, Freiburger L, et al. A C-terminal
HSP90 inhibitor restores glucocorticoid sensitivity and relieves a mouse allograft model of Cushing disease. Nat Med.
2015;21(3):276-280.
39. Bilodeau S, Vallette-Kasic S, Gauthier Y, et al. Role of Brg1
and HDAC2 in GR trans-repression of the pituitary POMC
gene and misexpression in Cushing disease. Genes Dev.
2006;20(20):2871-2886.
40. Mizoguchi Y, Kajiume T, Miyagawa S, Okada S, Nishi Y,
Kobayashi M. Steroid-dependent ACTH-produced thymic carcinoid: regulation of POMC gene expression by cortisol via methylation of its promoter region. Horm Res. 2007;67(5):257-262.
41. Araki T, Liu NA, Tone Y, et al. E2F1-mediated human POMC
expression in ectopic Cushing’s syndrome. Endocr Relat Cancer.
2016;23(11):857-870.
42. Araki T, Liu X, Kameda H, et al. EGFR induces E2F1-mediated
corticotroph tumorigenesis. J Endocr Soc. 2017;1(2):127-143.
43. Meinardi JR, Wolffenbuttel BH, Dullaart RP. Cyclic
Cushing’s syndrome: a clinical challenge. Eur J Endocrinol.
2007;157(3):245-254.
Downloaded from https://academic.oup.com/jes/article/5/6/bvab055/6205391 by Kobe Universtiy Library user on 16 September 2022
cycle via a glucocorticoid-driven positive-feedback mechanism.
Endocr J. 2018;65(7):755-767.
13. Seki Y, Morimoto S, Saito F, et al. ACTH-dependent cyclic
Cushing syndrome triggered by glucocorticoid excess through
a positive-feedback mechanism. J Clin Endocrinol Metab.
2019;104(5):1788-1791.
14. Kageyama K, Oki Y, Sakihara S, Nigawara T, Terui K, Suda T.
Evaluation of the diagnostic criteria for Cushing’s disease in
Japan. Endocr J. 2013;60(2):127-135.
15. Reincke M, Sbiera S, Hayakawa A, et al. Mutations in the
deubiquitinase gene USP8 cause Cushing’s disease. Nat Genet.
2015;47(1):31-38.
16. Chen J, Jian X, Deng S, et al. Identification of recurrent USP48
and BRAF mutations in Cushing’s disease. Nat Commun.
2018;9(1):3171.
17. Parvin R, Saito-Hakoda A, Shimada H, et al. Role of NeuroD1
on the negative regulation of Pomc expression by glucocorticoid. PLoS One. 2017;12(4):e0175435.
18. French FS, Macfie JA, Baggett B, Williams TF, Van Wyk JJ.
Cushing’s syndrome with a paradoxical response to dexamethasone. Am J Med. 1969;47(4):619-624.
19. Ronald DB, Brown Ronald D, Van Loon GR, Orth DN,
Liddle GW. Cushing’s disease with periodic hormonogenesis:
one explanation for paradoxical response to dexamethasone. J
Clin Endocrinol Metab. 1973;36(3):445-451.
20. Liberman B,
Wajchenberg BL,
Tambascia MA,
Mesquita CH. Periodic remission in Cushing’s disease
with paradoxical dexamethasone response: an expression of periodic hormonogenesis. J Clin Endocrinol Metab.
1976;43(4):913-918.
21. Kuchel O, Bolté E, Chrétien M, et al. Cyclical edema and hypokalemia due to occult episodic hypercorticism. J Clin Endocrinol
Metab. 1987;64(1):170-174.
22. Checchi S, Brilli L, Guarino E, et al. Cyclic Cushing’s disease
with paradoxical response to dexamethasone. J Endocrinol
Invest. 2005;28(8):741-745.
23. Nieman LK, Biller BM, Findling JW, et al.; Endocrine
Society. Treatment of cushing’s syndrome: an endocrine society clinical practice guideline. J Clin Endocrinol Metab.
2015;100(8):2807-2831.
24. Verhelst JA, Trainer PJ, Howlett TA, et al. Short and long-term
responses to metyrapone in the medical management of 91
patients with Cushing’s syndrome. Clin Endocrinol (Oxf).
1991;35(2):169-178.
25. White A, Ray DW, Talbot A, Abraham P, Thody AJ, Bevan JS.
Cushing’s syndrome due to phaeochromocytoma secreting the
precursors of adrenocorticotropin. J Clin Endocrinol Metab.
2000;85(12):4771-4775.
26. Schöneshöfer M, Fenner A, Claus M. Suppressive effect of
metyrapone on plasma corticotrophin immunoreactivity in
normal man. Clin Endocrinol (Oxf). 1983;18(4):363-370.
27. van Dam PS, van Gils A, Canninga-van Dijk MR, de Koning EJ,
Hofland LJ, de Herder WW. Sequential ACTH and catecholamine secretion in a phaeochromocytoma. Eur J Endocrinol.
2002;147(2):201-206.
...
論文の公開元へ
